Telehealth & Digital Health

A new firm, Nortiva Bio, is launching with tech from MIT to turn daily pills into monthly doses, starting with a contraceptive backed by the Gates Foundation.

BioCardia bets its future on Japan's fast-track approval for its heart therapy, a strategic pivot that could unlock global markets or break the bank.

A new drug from Cambrian Bio shows promise in activating a key metabolic switch. This could lead to treatments that burn fat while preserving muscle mass.

A health AI company is adding top cardiologists to its board, signaling a strategic shift to prove that algorithms can solve real-world health crises.

Beyond the ribbon-cutting, Healthconnect Texas's new hub is the physical anchor for an ambitious plan to merge clinical and social data, reshaping care for 27M.

A 'dream team' of pharma veterans has raised $180M to advance a next-gen oral drug, promising to transform the multi-billion dollar IBD market.

With a fresh $50M, Enhanced Group is selling a future of medically-guided peak performance. But can its controversial Games and peptide platform survive regulatory scrutiny?

Memo Therapeutics' Potravitug shows promise in a Phase II trial, offering the first real weapon against a common virus that threatens kidney transplants.

Dr. Glenn Parker's recent award is more than a trophy. It's a signal of a quiet revolution in healthcare—one that uses fintech to build national resilience.

A new spray-dried plasma could end reliance on freezers, transforming trauma care from the battlefield to rural ERs. But can Velico navigate the path to market?

Merck secures a pivotal FDA approval for its CAPVAXIVE vaccine, offering new hope for at-risk youth and challenging rivals in the high-stakes pneumococcal market.

A half-million dollar grant is just the start. A new public-private alliance is mobilizing to fight blast-induced brain injuries. Here's the story behind the numbers.

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

A new report projects the wellness market will hit $12.9T by 2031. This isn't just about yoga mats; it's a tech-fueled, Asia-led economic realignment.

After a 20-year drought, positive Phase 3 data for oral olorofim signals a safer, potent new option against a deadly fungus, promising a major market shake-up.

A landmark partnership aims to bring data-driven transparency to senior care, combining industry ratings with a national PR campaign to redefine quality.

Internet titan MrBeast is leveraging his billion-follower empire to tackle a critical blood shortage, aiming to save 1,000 lives in a single day.

GSK and Spero Therapeutics have won FDA approval for Utebzi, the first oral carbapenem for complex UTIs, a move that could slash healthcare costs.

With a $110M boost, Nyxoah is bringing its innovative, battery-free sleep apnea device to the US. Is this the disruption patients have been waiting for?

Delisted and facing market headwinds, Allurion is executing a reverse stock split. Can this financial maneuver revive its stock and fund its U.S. expansion?